Please login to the form below

Not currently logged in

Actavis in talks to buy Warner Chilcott

Companies confirm preliminary discussions have taken place

Actavis logoActavis has confirmed it is in talks to acquire Dublin-based, speciality pharma company Warner Chilcott, but said the discussions were at an early stage with no agreement yet reached.

It comes just weeks after a deal with Valeant thatValeant, that would reportedly have seen a multi-billion dollar merger between the Canadian company and New Jersey-based Actavis, fell through.

Actavis' interest in what it termed “a possible combination” with Warner Chilcott would bring it the company's branded pharmaceutical interests in women's healthcare, gastroenterology, urology and dermatology.

Primarily focused on the North American market, the US FDA last week approved two of Actavis' new oral contraceptives: norethindrone acetate and ethinyl estradiol chewable tablets, and ferrous fumarate tablets (known as Minastrin 24 FE).

Warner Chilcott, which had previously put itself on the market last year, brought in revenues of $593m in the first quarter of this year, a figure that was down 13 per cent on last year. 

Announcing the results, the company said the drop in sales were primarily due to generic competition for its anti-inflammatory product Asacol.

Buying Warner Chilcott would diversify Actavis' core strength in generics, a position that was boosted by last year's takeover of Actavis by Watson, with the parent company subsequently taking the Actavis name.

That deal made Actavis the third-largest generics company, after Teva and Novartis' Sandoz unit, with a presence in more than 60 markets.

13th May 2013

From: Research, Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

When is it time to rebrand?
The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....